2023-05-07T22:47:01+03:00[Europe/Moscow] en true <p>a</p>, <p>d</p>, <p>c</p>, <p>tumor agnostic </p>, <p>microsatellite instability high (MSI-H) </p>, <p>unresectable; MSI-H</p>, <p>a</p>, <p>a</p>, <p>antigen prostatic acid + GM-CSF</p>, <p>a</p>, <p>T-cell exhaustion </p>, <p>b</p>, <p>b</p>, <p>CTLA-4 binds to B7; PD1 binds PDL1 or PDL2</p>, <p>ipilimumab, novilumumab </p>, <p>Chmieric antigen Receptor therapy (CAR-T)</p>, <p>false; liquid only</p>, <p>leucel </p>, <p>cytokine release syndrome; ICANS</p>, <p>use an anti-IL-6 receptor antibody </p>, <p>ICANS</p>, <p>true</p>, <p>b</p>, <p>a</p>, <p>b</p>, <p>Multiple Myeloma </p>, <p>anemia, bone fracture, kidney failure, recurrent infection </p>, <p>increase in blood calcium, renal problems, anemia, bone damage </p>, <p>melphalan </p>, <p>autologous stem cell transplant (asct) </p>, <p>induction therapy, collection, freezing, high-dose chemo, thawing/infusion, engraftment/recovery </p>, <p>2; corticosteroid </p>, <p>bind to CRBN; activate ubiquitin ligase complex; transcription factors are targeted by proteasome </p>, <p>neutropenia, anemia, thrombocytopenia, infection</p>, <p>binds and activates apoptosis </p>, <p>Bortezomib</p>, <p>Ixazomib </p>, <p>revlimid; dexamethasone </p>, <p>d</p>, <p>c</p>, <p>c</p>, <p>e</p> flashcards
Cancer Immunotherapies

Cancer Immunotherapies

  • a

    Which Chemotherapy strategy is delivered BEFORE the main treatment, to make it easier to remove during surgery?

    a) neoadjuvant

    b) first line

    c) second line

    d) adjuvant

    e) palliative

    f) curative

  • d

    Which Chemo strategy is delivered AFTER primary treatment; given to prevent possible reoccurrence?

    a) neoadjuvant

    b) first line

    c) second line

    d) adjuvant

    e) palliative

    f) curative

  • c

    Which chemo strategy is also called salvage treatment?

    a) neoadjuvant

    b) first line

    c) second line

    d) adjuvant

    e) palliative

    f) curative

  • tumor agnostic

    -molecular signatures or biomarkers used to select therapies regardless of tumor site of origin

  • microsatellite instability high (MSI-H)

    -tumors that possess a molecular alteration that makes it difficult to repair damaged DNA; and produce abnormal proteins that make them easy to target

  • unresectable; MSI-H

    Pembrolizumab or KEYTRUDA is indicated for adults and children with _________ & ________.

  • a

    Which Cancer immunotherapy uses a patient's dendritic cells?

    a) Sipuleucel

    b) Ipilimumab

    c) Belantamab

    d) Daratumumab

    e) Selinexor

  • a

    Which Cancer immunotherapy is used to cause an immune response against cancer cells carrying the PAP antigen?

    a) Sipuleucel

    b) Ipilimumab

    c) Belantamab

    d) Daratumumab

    e) Selinexor

  • antigen prostatic acid + GM-CSF

    What are the components of Sipuleucel? (2)

  • a

    Which cancer immunotherapy is indicated for prostate cancer?

    a) Sipuleucel

    b) Ipilimumab

    c) Belantamab

    d) Daratumumab

    e) Selinexor

  • T-cell exhaustion

    -progressive loss of T-cell function due to prolonged antigen stimulation

  • b

    Which cancer immunotherapy is indicated for advanced metastatic melanoma?

    a) Sipuleucel

    b) Ipilimumab

    c) Belantamab

    d) Daratumumab

    e) Selinexor

  • b

    Which cancer immunotherapy can result in severe and fatal immune-mediated reactions like enterocolitis & hepatitis?

    a) Sipuleucel

    b) Ipilimumab

    c) Belantamab

    d) Daratumumab

    e) Selinexor

  • CTLA-4 binds to B7; PD1 binds PDL1 or PDL2

    T- cells can become unresponsive after what?

  • ipilimumab, novilumumab

    What are our CLTA-4 blockers? (2)

  • Chmieric antigen Receptor therapy (CAR-T)

    -genetic engineering of a patient’s T-cells to express fusion receptors with defined specificities for tumor-associated antigens

  • false; liquid only

    CAR-T has been proven effective in "liquid" hematologic cancers and solid tumors. T/F?

  • leucel

    -CAR-T therapeutics

  • cytokine release syndrome; ICANS

    What are the most common adverse effects associated with CAR-T therapeutics? (2)

  • use an anti-IL-6 receptor antibody

    How can we reverse Cytokine-Release syndrome?

  • ICANS

    -a toxic encephalopathy with aphasia and confusion that develop into confusion and in severe cases to coma, seizures, motor weakness, and cerebral edema.

  • true

    CRS and ICANS are both reversible. T/F?

  • b

    Which will appear in the blood stream?

    a) Lymphoma

    b) Leukemia

  • a

    Which is defined as a malignancy in both organs AND cells.

    a) Lymphoma

    b) Leukemia

  • b

    Which is defined as a progressive/malignant disease of blood forming organs?

    a) Lymphoma

    b) Leukemia

  • Multiple Myeloma

    -a tumor of antibody producing plasma cells in the bone marrow.

  • anemia, bone fracture, kidney failure, recurrent infection

    What are common symptoms in Multiple Myeloma? (4)

  • increase in blood calcium, renal problems, anemia, bone damage

    What does the CRAB criteria stand for?

  • melphalan

    -a potent chemotherapy drug that kills cancer cells and also blood forming cells.

  • autologous stem cell transplant (asct)

    -is the process of using a patient’s own (autologous) blood stem cells to help restore his or her blood supply and immune system

  • induction therapy, collection, freezing, high-dose chemo, thawing/infusion, engraftment/recovery

    What is the ASCT treatment course in order? (6)

  • 2; corticosteroid

    Combination therapy with ______ treatment backbones and 1 _______ is generally used for treatment of myeloma.

  • bind to CRBN; activate ubiquitin ligase complex; transcription factors are targeted by proteasome

    Lidomide MOA?

  • neutropenia, anemia, thrombocytopenia, infection

    What are major adverse effects associated with Lidomides?

  • binds and activates apoptosis

    Proteasome inhibitor MOA?

  • Bortezomib

    -a proteasome inhibitor used IV; can cause peripheral neuropathy, neutropenia, anemia, thrombocytopenia

  • Ixazomib

    - a proteasome inhibitor that is used orally; has similar SE's to Bortezomib except no peripheral neuropathy

  • revlimid; dexamethasone

    _______ and _______ are used in combination with Ixazomib.

  • d

    Which targets CD38 on MM cells to induce apoptosis?

    a) Sipuleucel

    b) Ipilimumab

    c) Belantamab

    d) Daratumumab

    e) Selinexor

  • c

    Which is an antibody conjugate indicated for patients who did not respond to at least 4 MM treatments?

    a) Sipuleucel

    b) Ipilimumab

    c) Belantamab

    d) Daratumumab

    e) Selinexor

  • c

    Which can cause ocular toxicity?

    a) Sipuleucel

    b) Ipilimumab

    c) Belantamab

    d) Daratumumab

    e) Selinexor

  • e

    Which medication is a small molecule drug that blocks XPO1 to cause accumulation in the nucleus?

    a) Sipuleucel

    b) Ipilimumab

    c) Belantamab

    d) Daratumumab

    e) Selinexor